Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta 1a for secondary progressive multiple sclerosis.

Richard A C Hughes1

  • 1Department of Neuroimmunology, Guy's, King's and St. Thomas School of Medicine, Guy's Hospital, London SE1 1 UL, UK. richard.a.hughes@kcl.ac.uk

Journal of the Neurological Sciences
|February 1, 2003
PubMed
Summary

Interferon beta (IFNb) shows reduced relapses and MRI lesions in secondary progressive multiple sclerosis (SPMS). However, only one trial demonstrated slowed disability progression, suggesting targeted use in relapsing SPMS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guillain-Barré Syndrome Disability Scale.

Journal of the peripheral nervous system : JPNS·2025
Same author

Guillain-Barré syndrome: History, pathogenesis, treatment, and future directions.

European journal of neurology·2024
Same author

An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy.

Journal of the peripheral nervous system : JPNS·2023
Same author

[Evidence based guidelines. Diagnosis and management of Guillain-Barré syndrome in ten steps].

Medicina·2021
Same author

Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.

Journal of neurology, neurosurgery, and psychiatry·2021
Same author

Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.

The Lancet. Neurology·2021

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Secondary progressive multiple sclerosis (SPMS) is a debilitating neurological condition.
  • Interferon beta (IFNb) is a treatment option for SPMS, but its efficacy is debated.
  • Understanding IFNb's impact on disease progression and imaging markers is crucial.

Purpose of the Study:

  • To review randomized controlled trials assessing interferon beta's efficacy in SPMS.
  • To analyze the impact of IFNb on relapse rates, MRI lesions, and disability progression.
  • To investigate factors influencing IFNb treatment outcomes in SPMS.

Main Methods:

  • Non-systematic review of four randomized trials (two IFNb1a, two IFNb1b).
  • Analysis of outcomes including relapse rates, new MRI lesions, and disability progression.

Related Experiment Videos

  • Post hoc analysis of patient subgroups based on pre-study relapse history.

    • Main Results:

    • All trials showed reduced relapse rates and new MRI lesions with IFNb.
    • Only one trial reported significant slowing of disability progression with IFNb.
    • Post hoc analyses indicated IFNb efficacy may be linked to pre-study relapse activity.

    Conclusions:

    • Current guidelines recommend IFNb for SPMS patients with recent disabling relapses.
    • Treatment effects on MRI were more pronounced in patients with recent relapses.
    • Further review is needed upon publication of full trial results.